Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

Hubei Minkang Pharma to Gain Stake in Hubei Merryclin Pharma

publication date: Mar 29, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hubei Minkang Pharma has signed a MoU with Hubei Merryclin Pharma to acquire a 30% to 51% interest in Merryclin. As part of the agreement, Minkang will gain immediate use of some GMP certified production facilities belonging to Merryclin that will expand its production. Minkang said the stake in Merryclin would require only a “modest” capital injection. Minkang makes TCM products along with some chemical drugs. More details....

Stock Symbol:  (OTCBB: HBMK)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Investor Forum
2013-Shanhai
September 4-5,2013
Shanghai, China

ChinaBio® Leadership Retraet
2013-Suzhou
October 24-25, 2013
Suzhou, China

ChinaBio® Investor Forum
2013-Wuhan
December 4-5,2013
Wuhan, China
>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

China Forum 2013
November 3, 2013
Vienna, Austria

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners